MetaGL+ is a new-generation patented compound, designed to naturally and effectively counteract hyperglycemia through agonist action on the GLP-1 receptor.
It acts directly on the expression of this receptor, increasing its effectiveness and half-life, while also improving intestinal absorption without compromising barrier integrity.
Preclinical tests conducted using Transwell® technology confirm high cell vitality, antioxidant capacity, and protection from oxidative stress, with efficient crossing of the intestinal barrier.
Action: modulation of plasma glucose and increased satiety.
Target organs: pancreas, CNS (indirect action)
MetaGL+ has undergone rigorous scientific testing to evaluate its effectiveness. After being metabolized by intestinal cells, the compound was tested on pancreatic cells to assess its effect on the insulin IRS-1 receptor and calcium channels involved in hormone release. This protocol allowed in vitro verification of MetaGL+’s ability to modulate circulating glucose and promote an effective insulin response.
The action of MetaGL+ has been studied through the analysis of key markers of glucose metabolism:
MetaGL+ represents an innovative and scientifically validated solution for the natural control of blood sugar and hunger, also contributing to weight management.
Please note that this website is not aimed at consumers as the information herein contained does not make reference to finished products; the website is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country.